MicroPort MedBot

MicroPort MedBot operates one of the broader surgical robotics portfolios globally, with seven NMPA-approved products by end of 2025 spanning laparoscopic, orthopedic, endovascular, single-port, telesurgical, dental, and bronchoscopic surgery. Listed on the Hong Kong Stock Exchange since November 2021, the company reported cumulative global commercial orders for its Toumai laparoscopic robot line exceeding 160 units by December 2025, with installations in nearly 40 countries.

Company Overview

Founded in 2015 as a subsidiary of MicroPort Scientific Corporation (00853.HK), MicroPort MedBot began its development of laparoscopic surgical robots in 2014 as an internal incubation project. The company is headquartered at 1601 Zhangdong Road, Zhang Jiang Hi-Tech Park, Shanghai.

According to Frost & Sullivan data, MicroPort MedBot remains the only surgical robot company worldwide with products covering five major surgical specialties: endoscopy (laparoscopic), orthopedics, pan-vascular intervention, natural orifice surgery, and percutaneous puncture. This broad portfolio positions the company uniquely against both international competitors and domestic peers.

Core Products

Toumai® Laparoscopic Surgical Robot

The flagship Toumai system became China’s first domestically developed four-arm laparoscopic surgical robot to receive NMPA approval in October 2021. Key specifications include 7 degrees of freedom robotic arms, sub-millimeter positioning accuracy, and proprietary force feedback technology. The system received CE Mark certification (MDR) in May 2024 and ANVISA approval in August 2024. Cumulative clinical procedures exceeded 15,000 cases as of 2025, covering nearly 400 different surgical procedures across urology, general surgery, thoracic surgery, and gynecology.

In March 2025, MicroPort received NMPA approval for Toumai SP, a single-port variant featuring snake-shaped instruments through a 2.5cm incision. Additionally, in May 2025, the Toumai Tele-Robotic Surgical System became the world’s first commercially approved tele-surgery platform, having completed nearly 500 remote procedures across 100+ countries with bidirectional latency under 150 milliseconds.

SkyWalker™ (Honghu) Orthopedic Surgical Robot

The SkyWalker system received NMPA approval in April 2022 for total knee arthroplasty (TKA), followed by FDA clearance in July 2022 and CE Mark in December 2022. It subsequently gained approvals from ANVISA (Brazil), TGA (Australia), and Health Canada, making it the only Chinese orthopedic robot certified across these major markets. The system has assisted in over 1,500 TKA procedures globally, with installations in China, United States, Germany, Italy, Belgium, Greece, Australia, and Brazil.

R-ONE® Vascular Intervention Robot

Developed through a joint venture with France’s Robocath S.A.S., R-ONE received NMPA approval in December 2023 as China’s first commercially available coronary PCI surgical robot. The system features dual-hand biomimetic twisting technology enabling 0-360° continuous rotation and sub-millimeter stepping accuracy. Following Siemens Healthineers’ exit from the PCI robot market, R-ONE became the sole coronary intervention robot available in China.

Mona Lisa Prostate Puncture Robot

Created through joint venture Shanghai Intbot with Singapore’s Biobot Surgical, Mona Lisa received NMPA approval in May 2023 as China’s first robotic prostate puncture positioning system. The system integrates MRI-ultrasound fusion algorithms for real-time guidance during transperineal prostate biopsy.

DFVision® 3D Electronic Laparoscope

MicroPort’s first product to receive NMPA approval (June 2021), DFVision features a chip-on-tip dual-lens design providing high-definition 3D imaging with reduced weight compared to traditional optical systems.

Duidao® (UniPath®) Bronchoscope Surgical Robot

Approved by NMPA in December 2024, the Duidao electronic bronchoscope surgical navigation system represents MicroPort’s eighth approved product and entry into natural orifice surgical robotics. The system integrates robotic precision control, flexible catheter navigation, and intelligent path planning for early diagnosis and treatment of deep and peripheral pulmonary lesions. With this approval, MicroPort achieved the distinction of becoming the world’s first company with commercially approved surgical robots spanning all major surgical categories.

Technology & Innovation

MicroPort MedBot has invested heavily in proprietary technology development, with R&D expenditure reaching RMB 309 million in 2024. The company has achieved 100% domestic production of core components for its main product lines, reducing dependence on imported servo motors and reducers.

The remote surgery platform represents a particular area of innovation. The company has established an intercontinental telesurgery network spanning six continents and over 100 countries. In 2024, surgeons using Toumai completed the world’s first satellite-based remote hepatectomy, marking the transition to “third-generation remote surgery” using satellite communications.

Market Presence

MicroPort MedBot reported revenue of RMB 175.7 million in the first half of 2025, representing 77% year-over-year growth. Overseas revenue exceeded RMB 100 million, growing 189% as international markets became the primary growth driver. Net losses narrowed to RMB 114.9 million, a 59% improvement from the prior year.

The Toumai system has achieved over 70 cumulative commercial orders globally, with 60%+ of domestic installations at provincial-level tertiary hospitals and top-100 national hospitals. The company has submitted regulatory applications in over 30 countries and regions, with registration approvals expected throughout 2025.

Key Milestones

• 2014: Commenced laparoscopic robot development as MicroPort internal project
• 2015: Shanghai MicroPort MedBot formally established
• 2021: NMPA approval for DFVision (June) and Toumai (October); Hong Kong IPO (November)
• 2022: SkyWalker receives NMPA, FDA, and CE approvals
• 2023: R-ONE and Mona Lisa receive NMPA approval
• 2024: Toumai receives CE Mark (MDR) and ANVISA; Core products exceed 100 cumulative orders; Duidao bronchoscope robot receives NMPA approval (December)
• 2025: Toumai SP and Tele-Robotic System receive NMPA approval; SkyWalker enters Canada; Toumai exceeds 15,000 clinical procedures

Frequently Asked Questions

What surgical robot products does MicroPort MedBot offer?

MicroPort MedBot offers eight NMPA-approved products: Toumai four-arm laparoscopic robot, Toumai SP single-port robot, Toumai Tele-Robotic System, DFVision 3D laparoscope, SkyWalker orthopedic robot, R-ONE vascular intervention robot, Mona Lisa prostate puncture robot, and Duidao (UniPath) bronchoscope surgical robot.

Is MicroPort MedBot publicly traded?

Yes, MicroPort MedBot is listed on the Hong Kong Stock Exchange under stock code 2252.HK since November 2021. The company raised approximately HK$2.77 billion in its IPO.

How does Toumai compare to da Vinci surgical robots?

Toumai offers comparable functionality to da Vinci with 7 degrees of freedom and 3D visualization, but at significantly lower cost—approximately RMB 13 million compared to RMB 20 million for da Vinci systems. Toumai uniquely offers commercially approved tele-surgery capability.

What international certifications has MicroPort MedBot obtained?

The company has obtained CE Mark for Toumai and SkyWalker, FDA clearance for SkyWalker and Mona Lisa, plus certifications from ANVISA (Brazil), TGA (Australia), and Health Canada across various products.